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Introduction {#sec001}
============

Colorectal cancer (CRC) is a heterogenous disease evolving from diverse genetic pathways and an accurate assessment of cancer based on tumor features would permit personalized cancer treatment \[[@pone.0128202.ref001],[@pone.0128202.ref002],[@pone.0128202.ref003]\]. Currently, anatomic and pathologic staging is still the most accurate predictor of patient outcome \[[@pone.0128202.ref004]\]. The discovery and validation of genetic markers determining the efficiency of metastatic progression of CRC is therefore an important area of research, with the potential value of defining the subset of patients at highest or lowest risk of relapse. One of the promising molecular markers investigated in CRC is the presence of tumor microsatellite instability (MSI) \[[@pone.0128202.ref005],[@pone.0128202.ref006],[@pone.0128202.ref007],[@pone.0128202.ref008]\].

CRC is generally divided into two well-known molecular pathways, including the chromosomal instability (CIN) pathway and the microsatellite instability (MSI) pathway. MSI is the result of deficient DNA mismatch repair (dMMR) \[[@pone.0128202.ref009]\]. A germline mutation in one of the MMR genes, including *MLH1*, *MSH2*, *MSH6* or *PMS2*, is the cause of dMMR in patients with Lynch syndrome, which is an inherited disorder that increases the risk of developing CRC \[[@pone.0128202.ref010],[@pone.0128202.ref011]\]. Deficient MMR is also observed in 10% to 20% of patients with sporadic CRC, of which the majority of dMMR tumors are due to hypermethylation of *MLH1* gene promoter, with *MSH2* and *MSH6* accounting for a smaller percentage \[[@pone.0128202.ref005]\]. Sporadic dMMR tumors, but not Lynch syndrome, frequently carry the activating somatic V600E mutation in the exon 15 of the *BRAF* oncogene \[[@pone.0128202.ref012],[@pone.0128202.ref013],[@pone.0128202.ref014]\]. Both sporadic and Lynch syndrome-associated tumors with dMMR status have distinct clinicopathologic features, such as preferential location in the proximal colon, prominent lymphocytic infiltrate, mucinous or signet ring differentiation, and association with a favorable prognosis. Data from the PETACC-3 trail reported that tumor specimens with dMMR status are more common in stage II disease than in stage III disease (22% *vs* 12%, *P* \< 0.001) and with a percentage of 3.5% in stage IV tumors. These results indicate that dMMR tumors have a decreased likelihood to metastasize and suggest a more favorable outcome \[[@pone.0128202.ref009],[@pone.0128202.ref015]\].

The Ras/Raf/MEK/ERK kinase cascade is involved in the control of cell proliferation, cell survival and invasion in CRC cancer cells \[[@pone.0128202.ref016]\]. *KRAS* is mutated in 35%-40% CRC and mutation of the *KRAS* protooncogene is an early event in development of these cancers, exerting a strong influence on the growth of colonic polyps and early cancers \[[@pone.0128202.ref017],[@pone.0128202.ref018]\]. Robust evidence suggests the predictive value of *KRAS* mutation in metastatic CRC treated with anti-EGFR targeted therapy \[[@pone.0128202.ref019],[@pone.0128202.ref020]\]. However, the clinical significance of *KRAS* mutation as a prognostic marker is controversial. Some studies reported no association with survival, whereas others suggested that patients with *KRAS* mutated tumors have poorer outcome for any mutation subtype \[[@pone.0128202.ref021],[@pone.0128202.ref022],[@pone.0128202.ref023],[@pone.0128202.ref024]\].

The association of MMR status, *KRAS* and *BRAF* mutations on clinical outcome are frequently documented. However, development of a more accurate prediction on clinical outcome using biomarker combinations remains a worthy area of investigation. Furthermore, in contrast to dMMR CRC, data on the presence of *KRAS* oncogenic mutations in proficient MMR (pMMR) CRC and their relationship with tumor progression are scarce. The aim of this study was to evaluate the prognostic role of MMR status in combination with *KRAS* mutations in 913 Chinese patients and characterize the specified subtypes with respect to clinicopathologic features.

Materials and Methods {#sec002}
=====================

Study population {#sec003}
----------------

Patients with resected, histologically proven CRC were eligible. The clinicopathological records of 913 patients with corresponding paraffin-embedded materials available for molecular analysis were retrospectively collected from the Department of Pathology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China from 2011 to 2013. A central pathology review was performed. Stratification factors included: number of metastatic regional lymph nodes (N1: 1--3 *vs* N2: ≥4), histologic grade (G1-2: well/moderately differentiated *vs* G3: poorly differentiated/ undifferentiated), tumor diameter, pT classification, histological subtype, tumor location, tumor size as well as the pTNM stage. The pTNM staging system of the 7th edition AJCC cancer staging was used. Evaluation of M stage was mainly according to confirmed pathological results and/or radiological data. Proximal tumor site included cecum, ascending, hepatic flexure and transverse colon; distal site included splenic flexure, descending and sigmoid colon. Mucinous differentiation in the tumor was defined by the presence of pools of extracellular mucin-containing clusters of carcinomatous cells. When \> 50% of analyzed tumor demonstrated mucinous differentiation, the tumor was classified as mucinous carcinoma. The study was approved by the Institute Review Board of the Cancer Hospital, Chinese Academy of Medical Sciences. Each participant signed an Institutional Review Board approved informed consent in accordance with current guidelines.

*KRAS* and *BRAF* ^*V600E*^ mutation analysis {#sec004}
---------------------------------------------

Assessment of *KRAS* and *BRAF* V600E mutational status was performed in the Molecular Pathology Laboratory of the Department of Pathology, Cancer Hospital, CAMS, using appropriate quality control procedures. Mutation status was determined using genomic DNA extracted from macrodissected formalin-fixed, paraffin-embedded tumor tissue. Both *KRAS* (codons 12 and 13) and *BRAF* (p.V600E) mutation tests were performed using a multiplex allele-specific PCR-based assay (ACCB, Beijing, China), together with the Stratagene Mx3000P (Agilent Technologies Inc, Santa Clara, CA), which assesses seven different potential mutations in *KRAS* codons 12 and 13 (*Gly12Ala*, *Gly12Asp*, *Gly12Arg*, *Gly12Cys*, *Gly12Ser*, *Gly12Val*, and *Gly13Asp*). Neither *KRAS* nor *BRAF* ^*V600E*^ mutated tumors were designated as wild-type *KRAS* subtype.

DNA mismatch repair proteins expression {#sec005}
---------------------------------------

MMR protein (MLH1, PMS2, MSH2 and MSH6) expression was performed as a routine practice in our pathological department. All samples were stained in an autostainer (Autostainer Link 48, Dako, Denmark). Four μm thick tissue sections were deparaffinized in xylene, rehydrated in graded alcohol and washed in distilled water. Ready-to-use primary mouse monoclonal antibodies included MLH1 antibody (ES05, Dako) and MSH2 antibody (FE11, Dako). Ready-to-use primary rabbit monoclonal antibodies included MSH6 antibody (EP49, Dako) and PMS2 antibody (EP51, Dako). MMR protein loss was defined as absence of nuclear staining in tumor cells but positive nuclear staining in normal colonic epithelial cells and lymphocytes. Tumors were designated as dMMR status if loss of at least one MMR protein was detected and pMMR if all proteins were intact.

*MLH1* promoter methylation analysis {#sec006}
------------------------------------

All DNA specimens were subjected to bisulfite modification using the EZ DNA Methylation Kit (Zymo Research, CA, USA) according to the manufacturer instructions. One μg of genomic DNA from each sample was bisulfite converted and eluted in 18μl elution buffer. Methylation-specific PCR (MSP) was conducted as previously described \[[@pone.0128202.ref025]\]. The primers used for this analysis were: 5'-AAT TAA TAG GAA GAG CGG ATA GC-3' and 5'-CCT CCC TAA AAC GAC TAC TAC CCG-3' for methylated *MLH1* promoter and 5'-TGA ATT AAT AGG AAG AGT GGA TAG T-3' and 5'-TCC CTC CCT AAA ACA ACT ACT ACC CA-3' for unmethylated *MLH1* promoter. MSP PCR primer specificity was confirmed as they did not amplify non-bisulphite-treated genomic DNA templates, and the MSP products of several primary tumors have been confirmed by direct sequencing with BigDye v3.1 (Applied Biosystems), indicating that our MSP system is specific.

Statistical analysis {#sec007}
--------------------

The primary objective of this study was to identify distinct clinicopathologic features associated with MMR status and *KRAS* mutation. Logistic regression models were used to detect associations of these characteristics with each of the *KRAS* mutations and MMR status. Kruskal-Wallis and χ^2^ (or Fisher's exact) tests were used to compare continuous and categorical variables, respectively. Univariate logistic regression models were used to further categorize and define the final covariables used for multivariable analysis. Statistical tests were two-sided, and *P* values of 0.05 were considered significant. For multiple comparisons, Bonferroni-adjusted *P* values were reported for the differences between *KRAS* mutation and MMR status (α = 0.05/6). Statistically significant characteristics based on univariate models were then included in multivariable models using stepwise and backwards model selection procedures. Odds ratios and their 95% confidence intervals were calculated. Statistics were carried out using SPSS software (version 16.0 of SPSS, Chicago, IL, USA).

Results {#sec008}
=======

A total of the 913 cases were evaluated by immunohistochemistry (IHC) for the presence or absence of MLH1, MSH2, MSH6 and PMS2 protein expression. Of the 69 cases (69/913, 7.5%) with dMMR, 49 had an absence of protein expression for MLH1/PMS2, 9 for MSH2/MSH6, 5 for MSH6 and 6 for PMS2 alone. In order to distinct Lynch syndrome-related CRC from sporadic MSI cancers, we performed the *MLH1* promoter methylation study. Among 49 cases with an absence of protein expression for MLH1/PMS2, 32.6% (16/49) cases had *MLH1* promoter methylation. Of them, *KRAS* mutations in *MLH1* methylated sporadic MSI tumors were 25% (4/16) and the mutation frequency was much lower than that of overall mutations, 36.9% (337/913) ([Fig 1](#pone.0128202.g001){ref-type="fig"}).

![Representive MSP (Methylation-specific PCR) results of *MLH1* methylation in colorectal cancer with loss of MLH1/PMS2 protein expression.](pone.0128202.g001){#pone.0128202.g001}

Patient and tumor characteristics with respect to the MMR status were shown in [Table 1](#pone.0128202.t001){ref-type="table"}. The mean age at presentation for dMMR tumors was 53.3±12.7 years, which was younger than that of pMMR tumors (*P* = 0.003). Overall, tumors with dMMR were more frequently located on the proximal side of the colon (72.4% *vs* 18.9%, *P* \< 0.0001) and were more likely to be poorly differentiated (34.8% *vs* 18.0%, *P* \< 0.001), compared with pMMR tumors. In addition, tumors with dMMR were also significantly associated with mucinous histological subtype (63.8% *vs* 32.7%, *P* \< 0.0001) and reduced lymph node metastasis (39.1% *vs* 54.6%, *P* = 0.01). There were no statistically significant differences in gender and pT stage.

10.1371/journal.pone.0128202.t001

###### Distributions of clinicopathologic characteristics by MMR status.

![](pone.0128202.t001){#pone.0128202.t001g}

  Characterics            pMMR (n = 844)   dMMR (n = 69)   *P*-value
  ----------------------- ---------------- --------------- ---------------------------------------------
  **Sex**                                                  0.54
   Male                   494 (58.5%)      43 (62.3%)      
   Female                 350 (41.5%)      26 (37.7%)      
  **Tumor Location**                                       \<0.0001
   Proximal colon         158 (18.9%)      42 (72.4%)      
   Distal colon           259 (31.0%)      14 (24.1%)      
   Rectum                 419 (50.1%)      2 (3.4%)        
  **pT stage**                                             0.06
   pT1-2                  117 (13.9%)      4 (5.8%)        
   pT3-4                  727 (86.1%)      65 (94.2%)      
  **pN stage**                                             0.01
   pN0                    383 (45.4%)      42 (60.9%)      
   pN1-2                  461 (54.6%)      27 (39.1%)      
  **Tumor Grade**                                          0.001
   G1-2                   692 (82.0%)      45 (65.2%)      
   G3                     152 (18.0%)      24 (34.8%)      
  **Histological type**                                    \<0.0001
   Mucinous               276 (32.7%)      44 (63.8%)      
   Non-mucinous           568 (67.3%)      25 (36.2%)      
  **Disease stage**                                        0.02
   I--II                  374 (44.3%)      41 (59.4%)      
   III--IV                470 (55.7%)      28 (40.6%)      
  **Age, y**                                               0.003[^†^](#t001fn002){ref-type="table-fn"}
   Mean (SD)              57.5±11.1        53.3±12.7       
   Median                 58.0             55.0            
   Range                  21.0--87.0       27.0--82.0      
  **Age, y**                                               0.008
   \<50                   197 (23.3%)      26 (37.7%)      
   ≥50                    647 (76.7%)      43 (62.3%)      
  **Tumor Size**                                           \<0.0001
   \<6cm                  658 (78.0%)      29 (42.0%)      
   ≥6cm                   186 (21.0%)      40 (58.0%)      

Abbreviations: MMR = mismatch repair; SD = standard deviation.

^†^ Two-sided Kruskal Wallis test

Others are two-sided χ^2^ test.

Mutations in *KRAS* and *BRAF* ^*V600E*^ were mutually exclusive. There were 6 cases with dMMR tumors that harbored *BRAF* ^*V600E*^ mutations and these cases were excluded from the analysis. *KRAS* mutations in codons 12 and 13 were observed in 36.9% (337/913) of all tumors. A higher frequency of *KRAS* mutations were detected in dMMR tumors (27/69, 39.1%) compared with pMMR tumors (310/844, 36.7%), although this difference did not reach statistical significance. Of the 27 dMMR and *KRAS*-mutated tumors, 16 cases were defined with loss of MLH1/PMS2, 7 with MSH2/MSH6 and 4 with PMS2 alone.

Patient and tumor characteristics with respect to both the MMR and *KRAS* mutation status were summarized in [Table 2](#pone.0128202.t002){ref-type="table"}. Of the 913 cases where both the MMR and *KRAS* mutation status were defined, 27 (2.9%) cases with dMMR were *KRAS* (+) and 42 (4.6%) were *KRAS* (-), whereas 310 (34.0%) cases with pMMR were *KRAS* (+) and 534 (58.5%) were *KRAS* (-). Among these four groups, significant differences were observed for gender {*KRAS* (+)/dMMR cases more likely to be male, *P* \< 0.0001}, age {*KRAS* (+)/dMMR more likely to have a younger age at diagnosis of disease, *P* = 0.0001}, grade {*KRAS* (-)/dMMR more likely to have lower grade disease, *P* = 0.002}, tumor location {*KRAS* (+) and *KRAS* (-)/dMMR cases more likely to be located in the proximal colon, *P* \< 0.0001}and lymph node metastasis {*KRAS* (+)/pMMR cases more likely to have higher pN stage, *P* = 0.004}. However, no differences were noted in the pT stage among these four groups.

10.1371/journal.pone.0128202.t002

###### Clinicopathological characteristics by *KRAS* mutation status and MMR status.

![](pone.0128202.t002){#pone.0128202.t002g}

  Characteristics         pMMR Mutant *KRAS* (n = 310)   pMMR Wild-type *KRAS* (n = 534)   *P*-value                                    dMMR Mutant *KRAS* (n = 27)   dMMR Wild-type *KRAS* (n = 42)   *P*-value                                     *P*-value (Compared with 4 groups)
  ----------------------- ------------------------------ --------------------------------- -------------------------------------------- ----------------------------- -------------------------------- --------------------------------------------- ---------------------------------------------
  **Sex**                                                                                  \<0.0001                                                                                                    0.27                                          \<0.0001
   Male                   152 (51.0%)                    342 (64.0%)                                                                    19 (70.4%)                    24 (57.1%)                                                                     
   Female                 158 (49.0%)                    192 (36.0%)                                                                    8 (29.6%)                     18 (42.9%)                                                                     
  **Tumor Location**                                                                       0.004                                                                                                       0.51[^§^](#t002fn004){ref-type="table-fn"}    \<0.0001
   Proximal               60 (20.9%)                     78 (14.7%)                                                                     16 (64.0%)                    26 (66.7%)                                                                     
   Distal                 72 (25.1%)                     187 (35.3%)                                                                    7 (28.0%)                     7 (17.9%)                                                                      
   Rectum                 155 (54.0%)                    264 (49.9%)                                                                    2 (8.0%)                      6 (15.4%)                                                                      
  **pT stage**                                                                             0.54                                                                                                        0.15[^‡^](#t002fn003){ref-type="table-fn"}    0.32[^§^](#t002fn004){ref-type="table-fn"}
   pT1-2                  40 (12.9%)                     77 (14.4%)                                                                     6 (22.2%)                     3 (7.1%)                                                                       
   pT3-4                  270 (87.1%)                    457 (85.6%)                                                                    21 (77.8%)                    39 (92.9%)                                                                     
  **pN stage**                                                                             0.007                                                                                                       0.43                                          0.004
   pN0                    123 (39.7%)                    263 (49.3%)                                                                    18 (66.7%)                    24 (57.1%)                                                                     
   pN1-2                  187 (60.3%)                    271 (50.7%)                                                                    9 (33.3%)                     18 (42.9%)                                                                     
  **Tumor Grade**                                                                          0.28                                                                                                        0.22                                          0.002
   G1-2                   260 (83.9%)                    432 (80.9%)                                                                    20 (74.1%)                    25 (59.5%)                                                                     
   G3                     50 (16.1%)                     102 (19.1%)                                                                    7 (25.9%)                     17 (40.5%)                                                                     
  **Histological type**                                                                    0.007                                                                                                       0.36                                          \<0.0001
   Non-mucinous           191 (61.6%)                    377 (70.6%)                                                                    8 (29.6%)                     17 (40.5%)                                                                     
   Mucinous               119 (38.4%)                    157 (29.4%)                                                                    19 (70.4%)                    25 (59.5%)                                                                     
  **Disease stage**                                                                        0.03                                                                                                        0.63                                          0.01
   I--II                  122 (39.4%)                    252 (47.2%)                                                                    17 (63.0%)                    24 (57.1%)                                                                     
   III--IV                188 (60.6%)                    282 (52.8%)                                                                    10 (37.0%)                    18 (42.9%)                                                                     
  **Age, y**                                                                               0.07[^†^](#t002fn002){ref-type="table-fn"}                                                                  0.001[^†^](#t002fn002){ref-type="table-fn"}   0.001[^†^](#t002fn002){ref-type="table-fn"}
   Mean (SD)              58.4 ± 10.8                    56.9 ± 11.3                                                                    51.0 ± 12.2                   54.8 ± 12.5                                                                    
   Median                 59.0                           58.0                                                                           51.0                          56.5                                                                           
   Range                  31.0--84.0                     21.0--87.0                                                                     27.0--77.0                    32.0--82.0                                                                     
  **Age, y**                                                                               0.06                                                                                                        0.35                                          0.009
   \< 50                  61 (19.7%)                     135 (25.3%)                                                                    12 (44.4%)                    14 (33.3%)                                                                     
   ≥ 50                   249 (80.3%)                    399 (74.7%)                                                                    15 (55.6%)                    28 (66.7%)                                                                     
  **Tumor Size**                                                                           0.61                                                                                                        0.50                                          \<0.0001
   \< 6cm                 245 (79.0%)                    414 (77.5%)                                                                    10 (37.0%)                    19 (45.2%)                                                                     
   ≥ 6cm                  65 (21.0%)                     120 (22.5%)                                                                    17 (63.0%)                    23 (54.8%)                                                                     

Abbreviations: MMR = mismatch repair; SD = standard deviation.

^†^Two-sided Kruskal Wallis test

^‡^Two-sided χ^2^ test with continuity correction

^§^ Fischer's exact test

Others are two-sided χ^2^ test

A *P* value for significance was adjusted for multiple hypothesis testing to *P* = 0.05/6 = 0.0083. Thus, a *P* value between 0.05 and 0.0083 should be regarded as of borderline significance.

When compared with those with *KRAS*(-)/pMMR tumors, patients with *KRAS*(+)/pMMR tumors were most likely to be female (49.0% *vs* 36.0%; OR = 1.85; 95% CI = 1.39 to 2.46; *P* \< 0.0001), to be proximal located (45.5% *vs* 29.3%; OR = 2.00; 95% CI = 1.30 to 3.08; *P* = 0.002), to have a mucinous histology (38.4% *vs* 29.4%; OR = 1.50; 95% CI = 1.11 to 2.01; *P* = 0.007), and to have increased lymph node metastasis (60.3% *vs* 50.7%; OR = 1.48; 95% CI = 1.11 to 1.96; *P* = 0.007) ([Table 3](#pone.0128202.t003){ref-type="table"}). To the contrary, compared with those with *KRAS*(-)/dMMR tumors, patients with *KRAS*(+)/dMMR tumors demonstrated no statistically significant differences in gender, tumor location, pT depth of invasion, lymph node metastasis, pTNM stage, and histologic grade. However, the mean age at presentation for *KRAS*(+)/dMMR tumors was 51.051.051.0 presentation for s,n, than that of *KRAS*(-)/dMMR tumors (*P* = 0.001).

10.1371/journal.pone.0128202.t003

###### Univariate logistic regression model associations between *KRAS* mutation status and MMR status.

![](pone.0128202.t003){#pone.0128202.t003g}

                                                  pMMR-Mutant *KRAS*    dMMR-Mutant *KRAS*                         
  ----------------------------------------------- --------------------- -------------------- --------------------- ------
   Female (referent: male)                        1.85 (1.39 to 2.46)   \<0.0001             0.56 (0.20 to 1.57)   0.37
   Proximal (referent: distal)                    2.00 (1.30 to 3.08)   0.002                1.63 (0.48 to 5.50)   0.43
   Proximal (referent: Rectum)                    1.31 (0.89 to 1.93)   0.17                 0.54 (0.10 to 3.02)   0.76
   pT 3--4 (referent: pT 1--2)                    1.14 (0.75 to 1.72)   0.54                 0.27 (0.06 to 1.19)   0.15
   pN 1--2 (referent: pN 0)                       1.48 (1.11 to 1.96)   0.007                0.67 (0.24 to 1.82)   0.43
   Low grade (referent: moderate to high grade)   0.81 (0.56 to 1.18)   0.28                 0.51 (0.18 to 1.48)   0.22
   Mucinous (referent: non-mucinous)              1.50 (1.11 to 2.01)   0.007                1.61 (0.58 to 4.53)   0.36
   pTNM III--IV (referent: pTNM I--II)            1.38 (1.04 to 1.83)   0.03                 0.78 (0.29 to 2.11)   0.63
   Age ≥ 50 years (referent: \< 50 years)         1.38 (0.98 to 1.94)   0.06                 0.63 (0.23 to 1.69)   0.35
   Tumor size \< 6cm (referent: ≥ 6cm)            1.09 (0.78 to 1.54)   0.61                 0.71 (0.26 to 1.92)   0.50

CI = confidence interval; dMMR = deficient mismatch repair; pMMR = proficient mismatch repair; OR = odds ratio.

^‡^ = Two-sided χ^2^ test with continuity correction

^§^ Fischer's exact test

Others are two-sided χ^2^ test.

A *P* value for significance was adjusted for multiple hypothesis testing to P = 0.05/6 = 0.0083. Thus, a *P* value between 0.05 and 0.0083 should be regarded as of borderline significance.

In the analysis using multivariable logistic regression models, we reviewed clinicopathologic characteristics in [Table 4](#pone.0128202.t004){ref-type="table"}. As shown multivariably, tumors with *KRAS*(+)/pMMR were statistically associated with proximal location, mucinous histology and increased lymph node metastasis.

10.1371/journal.pone.0128202.t004

###### Multivariate logistic regression model associations between patient, tumor and *KRAS* or *BRAF* ^*V600E*^ mutation status.

![](pone.0128202.t004){#pone.0128202.t004g}

  Characteristics                       pMMR-Mutant *KRAS*    
  ------------------------------------- --------------------- -------
  Female (referent: male)               2.73 (1.69 to 4.85)   0.001
  Proximal (referent: distal)           2.17 (1.39 to 3.33)   0.001
  pN 1--2 (referent: pN 0)              4.95 (2.84 to 6.38)   0.003
  Mucinous (referent: non-mucinous)     3.44 (1.11 to 7.47)   0.02
  pTNM III--IV (referent: pTNM I--II)   0.26 (0.03 to 2.02)   0.19

CI = confidence interval; pMMR = proficient mismatch repair; OR = odds ratio.

Discussion {#sec009}
==========

Defining tumor subtypes of CRC based on pathway-driven alterations has the potential to improve prognostication and guide targeted therapy. Distinct clinical and pathological features of CRC with different MMR status have long been identified \[[@pone.0128202.ref006],[@pone.0128202.ref026],[@pone.0128202.ref027],[@pone.0128202.ref028]\]. In this study, we demonstrated molecular and clinicopathological features of pMMR and dMMR tumors stratified by *KRAS* mutation status in a large cohort of consecutive Chinese CRC patients. Proficient MMR tumors that were nonmutated for *KRAS* and *BRAF* ^*V600E*^ were the most prevalent subtype and represented 58.5% (534/913) of our study cohort. Compared with this subtype, patients with *KRAS*(+)/pMMR tumors were more common in the proximal colon and to have a mucinous histology. Most importantly, patients with *KRAS*(+)/pMMR tumors showed increased lymph node metastasis among four subtypes and may have worse survival rate.

Consistent with the previous findings, our data suggest that tumors with dMMR status often exhibit poor differentiation, mucinous cell type, proximal location and reduced lymph node metastasis. In addition to its role in identifying unique pathological features of CRC, dMMR status has also been used as a prognostic marker and the guidance for Fluorouracil-based adjuvant chemotherapy \[[@pone.0128202.ref008]\]. Recent evidence indicated that CRC could be further classified into five prespecified subtypes using a biomarker combination of *KRAS* and *BRAF* ^*V600E*^ mutations, MMR status and *MLH1* methylation with statistically significant differences in clinicopathologic features and patient survival rates \[[@pone.0128202.ref029]\]. Thus, a biomarker-based classifier provides important prognostic information in CRC with implications for patient management. Evidence from other reports supported the idea that *KRAS* mutation and MMR status are genetic markers that arise early and remain biologically relevant throughout all stages of tumor progression \[[@pone.0128202.ref030],[@pone.0128202.ref031]\]. In addition, *KRAS* mutations found in primary tumors are preserved in recurrences and metastases. Consequently, we evaluated the prespecified tumor subtypes with respect to clinicopathologic features in biomarker combinations of *KRAS* mutations and MMR status.

Deficient MMR cancers typically originate in the proximal colon \[[@pone.0128202.ref015]\]. As expected, the vast majority of dMMR tumors in this study (72.4%) were from the proximal colon and this distribution was not influenced by *KRAS* mutations. Although most of the pMMR tumors were not likely to be proximal located, it is interesting that when pMMR tumors stratified by *KRAS* mutations, *KRAS* mutant tumors (20.9% proximal) were more likely to be proximal compared to *KRAS*(-)/pMMR tumors (14.7% proximal). Traditionally, colon cancers developed in the proximal bowel often created an environment in which CIMP (CpG Island Methylator Phenotype) is more likely to arise, and this synergizes with *BRAF* mutation to allow progression of serrated polyps \[[@pone.0128202.ref032]\]. However, recent evidence suggested that *KRAS* mutations could also be found in CIMP high and CIMP low tumors which were often located in the proximal colon \[[@pone.0128202.ref033]\]. This indicated that there were more comprehensive mechanisms underlying the location of colon cancer and the mutational profiles. Mucinous carcinoma is diagnosed when at least 50% of the tumor comprises secretory mucin and is often associated with dMMR status and serrated adenocarcinoma \[[@pone.0128202.ref034]\]. This is consistent with our finding that dMMR tumors demonstrated more mucinous differentiation than pMMR tumors (63.8% *vs* 32.7%). However, when stratified by *KRAS* mutation status, we observed that pMMR tumors with mutant *KRAS* phenotype exhibited more mucinous differentiation than wild type *KRAS* subtype (38.4% *vs* 29.4%). This is largely because *KRAS* mutation is not only linked to conventional adenomas but also associated with serrated adenomas in the development of colorectal cancer \[[@pone.0128202.ref035]\].

A significant association was found between the presence of lymph node metastases and pMMR tumors stratified by *KRAS* mutation status. Our findings revealed that pMMR tumors with *KRAS* mutation demonstrated more positive lymph nodes and pTNM III-IV stage of disease than tumors with *KRAS*(-)/pMMR status. This is consistent with findings from a smaller report, which demonstrated that the frequency of *KRAS* mutations was higher in pMMR lymph node positive tumors as compared to pMMR lymph node negative tumors \[[@pone.0128202.ref036],[@pone.0128202.ref037]\]. Our results indicate that the majority of pMMR tumors needed *KRAS* mutation to be able to metastasize and this activation was crucial for neoplastic cells to acquire invasive potential. Mutations in *KRAS* oncogene lead to alterations in encoded amino acids adjacent to the GTP binding pocket and reduced the GTPase activity of *KRAS* protein after guanine nucleotide activating protein (GAP) binding \[[@pone.0128202.ref038]\]. Both *in vitro* and *in vivo* experimental models, transfection of mutated, constitutively active forms of *KRAS* oncogene into previously noncancerous cells can lead to invasive and metastatic phenotypes. Ectopic expression of active *KRAS* in the murine NIH 3T3 fibroblast cell line resulted in increased invasion and acquisition of metastatic properties \[[@pone.0128202.ref039]\]. Using tail vein injection of transformed cells, *in vivo* models were observed by liver and lung metastasis \[[@pone.0128202.ref040]\]. In addition to the evidence obtained from cell and animal experiments, clinical studies have also displayed significant lymph node metastasis in *KRAS*(+)/pMMR tumors \[[@pone.0128202.ref036],[@pone.0128202.ref041]\]. Gene expression profiling reveals that genes involoving epithelial mesenchymal transition and matrix remodeling that can facilitate tumor invasion and metastasis are up-regulated in mutant *KRAS*-pMMR tumors \[[@pone.0128202.ref042]\]. Consequently, *KRAS* oncogenic activation was shown to be an important mediator of tumor cell invasion and metastasis in pMMR tumors.

The frequency of *KRAS* mutations in Lynch syndrome-related CRC and sporadic CRC is almost the same. However, *KRAS* mutations are significantly more frequent in Lynch syndrome-related CRC than that in sporadic MSI-H CRCs \[[@pone.0128202.ref037],[@pone.0128202.ref043]\]. Lynch syndrome-related CRC tend to be early-onset and proximal location. So this may explain the younger age and proximal location observed in *KRAS*+/MSI tumors. Despite these positive findings, our study has some limitations. First, because this is a retrospectively study, it is hard to collect the blood or saliva sample from patients to detect germline mutations to further distinguish the Lynch syndrome-related CRC from sporadic cancer. So we could not calculate the precise frequency of *KRAS* mutations in hereditary CRCs, however, it is sure that the Lynch syndrome-related CRC in our study showed preferentially *KRAS* mutations. Second, we did not examine other less common mutations in *KRAS* codons 61, 117 and 146, which also contributed to the oncogenic transformation of tumor cells.

This study suggests that specific epidemiologic and clinicopathologic characteristics are associated with MMR status stratified by *KRAS* mutation in CRC. Knowledge of MMR and *KRAS* mutation status may enhance molecular pathologic staging of CRC patients and metastatic progression can also be estimated based on the combination of these biomarkers. Validation of additional genetic biomarkers will help to refine management decisions for individual patients based on tumor biology. Importantly, this may also aid the development of novel therapeutic targets to aid treatment of these aggressive cancers.
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